U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850453) titled 'Vortosiran for VTE Prevention' on Sept. 17.
Brief Summary: Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop treatment early. Both cancer and chemotherapy further increase the risk of clot formation.
Vortosiran is an injectable therapy that lowers Factor XI (one of the body's natural clotting helpers) production in the liver, leading to a strong and long-lasting reduction in blood clotting activity with less risk of bleeding compared to current available tr...